Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
07:25pm, Tuesday, 01'st Aug 2023
Exelixis (EXEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.22 per share a year ago.
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
09:08am, Saturday, 29'th Jul 2023
As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new
7 Best Cancer Stocks to Invest in Now
07:00am, Friday, 28'th Jul 2023
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which hav
EXEL or RGEN: Which Is the Better Value Stock Right Now?
01:08pm, Tuesday, 25'th Jul 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
08:08am, Thursday, 20'th Jul 2023
The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o
Exelixis: Stock Likely To Break Out Of 5-Year Inertia
02:00am, Tuesday, 18'th Jul 2023
Exelixis, an oncology-focused company, has reported a sixth consecutive profitable year in 2022, with about 30% revenue growth due to increased sales of its drug, cabozantinib. EXEL reported total rev
3 No-Brainer Stocks to Buy With $200 Right Now
05:21am, Wednesday, 21'st Jun 2023
Every correction and bear market in the major stock indexes has marked an ideal buying opportunity for long-term investors. These three phenomenal businesses have the perfect blend of competitive adva
Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
12:38pm, Thursday, 08'th Jun 2023
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology
05:49am, Sunday, 28'th May 2023
Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as Genentech, contribute to Exelixis' impressive financial performance and market presence. Exelixis'
2 Under-the-Radar Biotech Stocks to Buy in 2023
09:53am, Wednesday, 24'th May 2023
Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
09:30am, Saturday, 20'th May 2023
Axsome has several catalysts in the works that could boost its stock price. Exelixis is working on new drugs to expand its footprint in oncology.
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
03:59pm, Wednesday, 10'th May 2023
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
10:09pm, Tuesday, 09'th May 2023
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates
08:37pm, Tuesday, 09'th May 2023
Exelixis (EXEL) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.21 per share a year ago.
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
04:05pm, Tuesday, 25'th Apr 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00
